ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program

Urology

Volumn 77, Issue 3, 2011, Pages 763.e1-763.e6

  Isharwal, Sumit ^c   Makarov, Danil V ^b   Sokoll, Lori J ^a   Landis, Patricia ^a   Marlow, Cameron ^a   Epstein, Jonathan I ^a   Partin, Alan W ^a   Carter, H Ballentine ^a   Veltri, Robert W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER THERAPY; COHORT ANALYSIS; DISEASE SURVEILLANCE; DNA CONTENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HEALTH INDEX;

EID: 79952336412     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.07.526     Document Type: Article

References (30)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics CA Cancer J Clin 59 2009 225 249
2. G. Draisma, R. Boer, and S.J. Otto Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for prostate cancer J Natl Cancer Inst 95 2003 868 878 (Pubitemid 36833878)
3. F.H. Schroder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
4. G.L. Andriole, E.D. Crawford, and R.L. Grubb III Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 2009 1310 1319
5. H.B. Carter, A. Kettermann, and C. Warlick Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience J Urol 178 2007 2359 2364
6. J.I. Epstein, P.C. Walsh, and M. Carmichael Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 271 1994 368 374 (Pubitemid 24037911)
7. M.H. Kawachi, R.R. Bahnson, and M. Barry NCCN clinical practice guidelines in oncology: prostate cancer early detection J Natl Compr Cancer Netw 8 2010 240 262
8. S. Isharwal, D.V. Makarov, and H.B. Carter DNA content in the diagnostic biopsy for benign-adjacent and cancer-tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programme BJU Int 105 2010 329 333
9. D.V. Makarov, S. Isharwal, and L.J. Sokoll Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer Clin Cancer Res 15 2009 7316 7321
10. J. Peter, C. Unverzagt, and T.N. Krogh Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry Cancer Res 61 2001 957 962 (Pubitemid 32174411)
11. Weinzierl CF, Su SX, Pierson TB, et al. Measuring [-2]proPSA in serum: analytical performance of the Access p2PSA assay from Beckman Coulter. Presented at the Annual Meeting of the American Association for Clinical Chemistry, abstract C-38, 2007.
12. F.E. Harrell Jr, R.M. Califf, and D.B. Pryor Evaluating the yield of medical tests JAMA 247 1982 2543 2546 (Pubitemid 12155954)
13. A. Bill-Axelson, L. Holmberg, and F. Filen Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group 4 randomized trial J Natl Cancer Inst 100 2008 1144 1154
14. A. Khatami, G. Aus, and J.E. Damber PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section Int J Cancer 120 2007 170 174
15. M. Borre, B. Stausbol-Gron, and J. Overgaard p53 accumulation associated with Bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting J Urol 164 2000 716 721 (Pubitemid 30637609)
16. S. Jhavar, J. Bartlett, and G. Kovacs Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance Prostate Cancer Prostatic Dis 12 2009 143 147
17. M. Borre, B. Nerstrom, and J. Overgaard Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting Clin Cancer Res 6 2000 1882 1890 (Pubitemid 30305085)
18. F. Demichelis, K. Fall, and S. Perner TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort Oncogene 26 2007 4596 4599 (Pubitemid 47037039)
19. N.J. van As, N.M. de Souza, and S.F. Riches A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance Eur Urol 56 2009 981 988
20. J.J. Tosoian, S. Loeb, and A. Kettermann Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program J Urol 183 2010 534 538
21. A.E. Ross, S. Loeb, and P. Landis Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a Prostate Cancer Surveillance Program J Clin Oncol 28 2010 2810 2816
22. L.J. Sokoll, D.W. Chan, and S.D. Mikolajczyk Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0 ng/mL total PSA range: preliminary analysis Urology 61 2003 274 276 (Pubitemid 36206515)
23. L. Sokoll, M.G. Sanda, and Z. Feng A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness Cancer Epidemiol Biomarkers Prev 19 2010 1193 1200
24. B.V. Le, C.R. Griffin, and S. Loeb [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study J Urol 183 2010 1355 1359
25. A.D. Deitch, G.J. Miller, and W.R.W. deVere Significance of abnormal diploid DNA histograms in localized prostate cancer and adjacent benign prostatic tissue Cancer 72 1993 1692 1700 (Pubitemid 23249300)
26. U.R. Chandran, R. Dhir, and C. Ma Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors BMC Cancer 5 2005 45
27. S. Isharwal, M.C. Miller, and J.I. Epstein Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy Int J Cancer 123 2008 2636 2643
28. S. Isharwal, M.C. Miller, and J.I. Epstein DNA ploidy as surrogate for biopsy Gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction Urology 73 2009 1092 1097
29. B. Tribukait Nuclear deoxyribonucleic acid determination in patients with prostate carcinomas: clinical research and application Eur Urol 23 suppl 2 1993 64 76 (Pubitemid 23166924)
30. J. Adolfsson, B. Tribukait, and S. Levitt The 20-yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity Eur Urol 52 2007 1028 1035 (Pubitemid 47332043)